Artour Torossian, MD
Radiation Oncology · Palmdale, CANPI 1851656953
Payments from drug & device makers
Across 29 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$111
- Amgen$79
- Novocure Inc.$60
- Sumitomo Pharma America, Inc.$48
- Johnson & Johnson$45
- Bayer$44
- plus $254 from 12 others
What the payments were for
- Food & beverage$641100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 2 | $111 |
| Amgen | 4 | $79 |
| Novocure Inc. | 3 | $60 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Johnson & Johnson | 3 | $45 |
| Bayer | 2 | $44 |
| Novartis | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $30 |
| Incyte Corporation | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| EMD Serono, Inc. | 1 | $26 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| Pfizer | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Varian Medical Systems, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
How this compares
$641 in reported general payments places this provider in the 50th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 33 | $3,511 |
| Tamsulosin Hcl | 77 | $1,665 |
| Lidocaine Hcl ViscousLidocaine Hcl | 34 | $1,122 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 34 | $1,032 |
| Bicalutamide | 22 | $758 |
| Ondansetron OdtOndansetron | 17 | $539 |
| Dexamethasone | 46 | $522 |
| Oxycodone Hcl | 26 | $424 |
| Finasteride | 14 | $274 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $174 |
| Famotidine | 17 | $156 |
| Lorazepam | 20 | $43 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Palmdale
- Loren Mellla Jolla$10M
- Hyun KimDuarte$6M
- Megan DalyOrange$4.5M
- Percy LeeIrvine$2.4M
- Felix FengSan Francisco$1.8M
- Jeffrey WongDuarte$1.7M
- Arta MonjazebSacramento$1.5M
- Rakesh PatelLos Gatos$1.3M
- Maximilian DiehnStanford$1.2M
- Rizwan NuraniApple Valley$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.